Jump to content

New KRAS Clinical Trials


Recommended Posts


Ph I/II trial evaluating our KRAS G12C inhibitor, MRTX 849 as monotherapy & in combination with other agents in NSCLC and other tumors.



Sapphire study. Ph III comparing sitravatinib+nivolumab vs. docetaxel in NSCLC patients who progressed on prior PD-1/PD-L1 based therapy


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.